Jundishapur Journal of Natural Pharmaceutical Products

Published by: Kowsar

Verapamil and Rifampin Effect on P-Glycoprotein Expression in Hepatocellular Carcinoma

Amir Jalali 1 , * , Sepideh Ghasemian 1 , Hossein Najafzadeh 2 , Hamid Galehdari 3 , Masoud Reza Seifi 4 , Fateme Zangene 5 and Shaiesteh Dehdardargahi 6
Authors Information
1 Toxicology Research Center, Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
2 Department of Pharmacology, Faculty of Veterinary Medicine, Shahid Chamran University, Ahvaz, IR Iran
3 Department of Genetic, Faculty of Sciences, Shahid Chamran University, Ahvaz, IR Iran
4 Department of Virology, Faculty of Veterinary Medicine, Shahid Chamran University, Ahvaz, IR Iran
5 Department of Pharmacology and Toxicology, Faculty of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
6 School of Medicine, Arvand Medical Science University, International Branch of Jundishapur University of Medical Sciences, Abadan, IR Iran
Article information
  • Jundishapur Journal of Natural Pharmaceutical Products: November 01, 2014, 9 (4); e17741
  • Published Online: October 10, 2014
  • Article Type: Research Article
  • Received: January 19, 2014
  • Revised: July 26, 2014
  • Accepted: September 6, 2014
  • DOI: 10.17795/jjnpp-17741

To Cite: Jalali A, Ghasemian S, Najafzadeh H, Galehdari H, Seifi M R, et al. Verapamil and Rifampin Effect on P-Glycoprotein Expression in Hepatocellular Carcinoma, Jundishapur J Nat Pharm Prod. 2014 ; 9(4):e17741. doi: 10.17795/jjnpp-17741.

Copyright © 2014, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
  • 1. Roberti A, La Sala D, Cinti C. Multiple genetic and epigenetic interacting mechanisms contribute to clonally selection of drug-resistant tumors: current views and new therapeutic prospective. J Cell Physiol. 2006; 207(3): 571-81[DOI][PubMed]
  • 2. Li Z, Hu S, Wang J, Cai J, Xiao L, Yu L, et al. MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells. Gynecol Oncol. 2010; 119(1): 125-30[DOI][PubMed]
  • 3. Pajic M, Iyer JK, Kersbergen A, van der Burg E, Nygren AO, Jonkers J, et al. Moderate increase in Mdr1a/1b expression causes in vivo resistance to doxorubicin in a mouse model for hereditary breast cancer. Cancer Res. 2009; 69(16): 6396-404[DOI][PubMed]
  • 4. Liu ZH, He YP, Zhou Y, Zhang P, Qin H. Establishment and identification of the human multi-drug-resistant cholangiocarcinoma cell line QBC939/ADM. Mol Biol Rep. 2011; 38(5): 3075-82[DOI][PubMed]
  • 5. van Waterschoot RA, Lagas JS, Wagenaar E, van der Kruijssen CM, van Herwaarden AE, Song JY, et al. Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity. Cancer Res. 2009; 69(23): 8996-9002[DOI][PubMed]
  • 6. Burger H, Foekens JA, Look MP, Meijer-van Gelder ME, Klijn JG, Wiemer EA, et al. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin Cancer Res. 2003; 9(2): 827-36[PubMed]
  • 7. Chen F, Wang T, Wang J, Wang ZQ, Qian M. Levistolide A overcomes P-glycoprotein-mediated drug resistance in human breast carcinoma cells. Acta Pharmacol Sin. 2008; 29(4): 458-64[DOI][PubMed]
  • 8. Dong X, Mattingly CA, Tseng MT, Cho MJ, Liu Y, Adams VR, et al. Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP. Cancer Res. 2009; 69(9): 3918-26[DOI][PubMed]
  • 9. Al-Rejaie SS, Aleisa AM, Al-Yahya AA, Bakheet SA, Alsheikh A, Fatani AG, et al. Progression of diethylnitrosamine-induced hepatic carcinogenesis in carnitine-depleted rats. World J Gastroenterol. 2009; 15(11): 1373-80[PubMed]
  • 10. Fujii T, Fuchs BC, Yamada S, Lauwers GY, Kulu Y, Goodwin JM, et al. Mouse model of carbon tetrachloride induced liver fibrosis: Histopathological changes and expression of CD133 and epidermal growth factor. BMC Gastroenterol. 2010; 10: 79[DOI][PubMed]
  • 11. Shaarawy SM, Tohamy AA, Elgendy SM, Elmageed ZY, Bahnasy A, Mohamed MS, et al. Protective effects of garlic and silymarin on NDEA-induced rats hepatotoxicity. Int J Biol Sci. 2009; 5(6): 549-57[PubMed]
  • 12. Nermin AH, Sadik SA,, Maraghy EL,, Manal FL. Diethylnitrosamine-induced hepatocarcinogenesis in rats: possible chemoprevention by blueberries. Afr J Biochem Res. 2008; 2(1): 81-7
  • 13. Ikeda H, Nakano G, Nagashima K, Sakamoto K, Harasawa N, Kitamura T, et al. Verapamil enhancement of antitumor effect of cis-diamminedichloroplatinum(II) in nude mouse-grown human neuroblastoma. Cancer Res. 1987; 47(1): 231-4[PubMed]
  • 14. Holmstock N, Gonzalez FJ, Baes M, Annaert P, Augustijns P. PXR/CYP3A4-humanized mice for studying drug-drug interactions involving intestinal P-glycoprotein. Mol Pharm. 2013; 10(3): 1056-62[DOI][PubMed]
  • 15. Ghasemian S, Najafzadeh H, Seifi MR, Jalali A, Galehdari H. Developing high performance and cost effective real time (PCR) for P-glycoprotein gene expression analysis in rat. Afr J Biotech. 2012; : 11501-8
  • 16. Bansal T, Mishra G, Jaggi M, Khar RK, Talegaonkar S. Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. Eur J Pharm Sci. 2009; 36(4-5): 580-90[DOI][PubMed]
  • 17. Meister S, Frey B, Lang VR, Gaipl US, Schett G, Schlotzer-Schrehardt U, et al. Calcium channel blocker verapamil enhances endoplasmic reticulum stress and cell death induced by proteasome inhibition in myeloma cells. Neoplasia. 2010; 12(7): 550-61[PubMed]
  • 18. Herzog CE, Tsokos M, Bates SE, Fojo AT. Increased mdr-1/P-glycoprotein expression after treatment of human colon carcinoma cells with P-glycoprotein antagonists. J Biol Chem. 1993; 268(4): 2946-52[PubMed]
  • 19. Chaudhary PM, Roninson IB. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst. 1993; 85(8): 632-9[PubMed]
  • 20. Lee CH, Bradley G, Ling V. Overexpression of the class II P-glycoprotein gene in primary rat hepatocyte culture: evidence for increased mRNA stability. Cell Growth Differ. 1995; 6(3): 347-54[PubMed]
  • 21. Kren BT, Trembley JH, Steer CJ. Alterations in mRNA stability during rat liver regeneration. Am J Physiol. 1996; 270(5 Pt 1)-77[PubMed]
  • 22. Larsen UL, Hyldahl Olesen L, Guldborg Nyvold C, Eriksen J, Jakobsen P, Ostergaard M, et al. Human intestinal P-glycoprotein activity estimated by the model substrate digoxin. Scand J Clin Lab Invest. 2007; 67(2): 123-34[DOI][PubMed]
  • 23. Becquemont L, Camus M, Eschwege V, Barbu V, Rey E, Funck-Brentano C, et al. Lymphocyte P-glycoprotein expression and activity before and after rifampicin in man. Fundam Clin Pharmacol. 2000; 14(5): 519-25[PubMed]
  • 24. Asghar A, Gorski JC, Haehner-Daniels B, Hall SD. Induction of multidrug resistance-1 and cytochrome P450 mRNAs in human mononuclear cells by rifampin. Drug Metab Dispos. 2002; 30(1): 20-6[PubMed]
  • 25. Ott M, Fricker G, Bauer B. Pregnane X receptor (PXR) regulates P-glycoprotein at the blood-brain barrier: functional similarities between pig and human PXR. J Pharmacol Exp Ther. 2009; 329(1): 141-9[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments